Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,062 recruiting studies in this area right now.
By phase
- Not applicable3,004
- Phase 21,058
- Phase 1794
- Phase 1/Phase 2439
- Phase 3436
- Phase 4233
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis329
- Multiple Myeloma328
- Asthma193
- Lymphoma178
- Rheumatoid Arthritis131
- Type 1 Diabetes131
- Atopic Dermatitis124
- Systemic Lupus Erythematosus119
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases77
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca63
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California497
- Maryland199
- Alabama177
- Florida152
- Arizona148
- Massachusetts117
- New York116
- Texas112
- Colorado82
- Illinois82
Recruiting studies6,062 total
- NCT07079150Recruiting
Long-term pegylated interferon study for HBV families with poor outcomes
This study looks at how well pegylated interferon alpha-2b works over the long term for people with chronic hepatitis B who come from families where the virus has caused serious liver problems like cirrhosis or liver cancer. The goal is to see if this treatment can help prevent these bad outcomes in family members.
Xi'an, ShaanxiAges 18–70 - NCT07083856Recruiting
Reiki and self-acupressure for people with MS
This study tests two relaxing therapies — Reiki (a gentle hands-on energy technique) and self-acupressure (applying mild finger pressure on specific points) — for people with multiple sclerosis. It looks at how these treatments affect symptoms like anxiety, depression, and fatigue.
Muğla, Fethi̇yeAges 18–75 - NCT07084662RecruitingPhase 2/Phase 3
Xinlikang capsule for fatigue after lymphoma treatment
This trial tests a Chinese herbal capsule, Xinlikang, to see if it helps reduce fatigue and improve immune function after chemotherapy for diffuse large B-cell lymphoma. It is for people who have finished their first treatment and still feel very tired.
Guangzhou, GuangdongAges 18 years+ - NCT07079423RecruitingPhase 2
Teclistamab for new advanced AL amyloidosis
This trial tests a new drug called teclistamab for people newly diagnosed with advanced (stage IIIB) AL amyloidosis, a condition where abnormal proteins build up and damage organs. The goal is to see if teclistamab can help control the disease.
BeijingAges 18 years+ - NCT07077486RecruitingPhase 4
Testing telitacicept vs cyclophosphamide for lupus lung disease
This trial tests if a new drug called telitacicept works better than a standard lupus medicine (cyclophosphamide) to improve lupus-related lung scarring (interstitial lung disease). It might be an option if your breathing tests are still good enough.
Wuhan, HubeiAges 18–80 - NCT07081126Recruiting
Daratumumab for late antibody-mediated rejection in kidney transplant
This trial tests whether daratumumab can help treat a type of rejection that happens more than a year after a kidney transplant. It may be an option for people who have biopsy-proven antibody-mediated rejection and new donor-specific antibodies.
MartinAges 18 years+ - NCT07077512RecruitingPhase 2
CAR-T cells plus immunotherapy for advanced B-cell lymphoma
This trial tests a combination of two treatments: a CAR-T cell therapy (relmacabtagene autoleucel) and an immunotherapy drug (sintilimab) for people with certain types of B-cell lymphoma that have come back or stopped responding to other treatments. The goal is to see if this combination can help control the cancer.
GuangzhouAges 18–70 - NCT07076043RecruitingPhase 4
HIV prevention for young women getting reproductive health care
This study offers different forms of HIV prevention medicine (PrEP) to young women ages 18–30 who are visiting clinics for reproductive health services like family planning or postnatal care. It aims to see which delivery method works best for you.
Thika, Kiambu CountyAges 18–30 - NCT07083882RecruitingPhase 2
Capsule transplant for newly diagnosed type 1 diabetes
This study tests if taking capsules with processed donor stool can help preserve insulin-making cells in people recently diagnosed with type 1 diabetes. The treatment aims to slow the loss of insulin production.
AmsterdamAges 18–45 - NCT07077304Recruiting
Cardiac imaging study for inflammatory heart diseases
This study uses heart scans (MRI or nuclear imaging) to better understand inflammatory heart conditions. If you have a suspected inflammatory heart disease and are already scheduled for one of these scans, you may be able to join.
ParisAges 18 years+ - NCT07085676RecruitingPhase 1
CAR-T cell therapy for autoimmune diseases that resist treatment
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
JerusalemAges 18–80 - NCT07084480Recruiting
A study on giant cell arteritis for precision medicine
This trial looks at giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) to find more personalized treatments. If you have been diagnosed with either condition, you may be able to help researchers understand these diseases better.
WürzburgAges 18 years+ - NCT07079735RecruitingPhase 2/Phase 3
Preventing CMV after heart transplant
This trial compares two antiviral drugs, valganciclovir and letermovir, to see which works better at preventing CMV infection after a heart transplant. If you've had a heart transplant and haven't started preventive treatment yet, this study may be for you.
New York, New YorkAges 18–99 - NCT07085039RecruitingPhase 2
Ruxolitinib for previously treated idiopathic multicentric Castleman disease
This trial tests the drug ruxolitinib for people with idiopathic multicentric Castleman disease (iMCD) whose symptoms are not well controlled by standard anti-IL-6 therapy. Ruxolitinib is a pill taken by mouth that may help reduce inflammation and improve symptoms.
Philadelphia, PennsylvaniaAges 18–80 - NCT06955832Recruiting
Early MS Brain Lesion Detection Using Advanced MRI
This study tests a special type of MRI called Phase Sensitive Inversion Recovery to find brain lesions (areas of damage) in people with multiple sclerosis. The goal is to catch these lesions earlier to help guide treatment.
Banhā, Qalyubia GovernorateAges 15–65 - NCT06979271Recruiting
Testing a new drug combo for tough rheumatoid arthritis
This trial tests whether combining Telitacicept and Tofacitinib can help people with rheumatoid arthritis that hasn't improved with at least two other advanced treatments. The goal is to see if these drugs work better together for hard-to-treat cases.
Hangzhou, ZhejiangAges 18–85 - NCT05004493Recruiting
Plasma exchange patient registry and sample collection
This study collects information and blood or other samples from people who are getting plasma exchange therapy. The goal is to build a registry (a organized database) that researchers can use to better understand and improve care.
Iowa City, IowaAges 12–99 - NCT06687434Recruiting
Carb counting vs. simple meal-size estimation for type 1 diabetes
This study compares two ways of estimating meal size for people with type 1 diabetes who use automated insulin delivery systems. One method is detailed carb counting, the other is a simpler, qualitative estimate of meal size. The goal is to see which approach works better for managing blood sugar.
Petah TikvaAges 6–18 - NCT05759793RecruitingPhase 1
CAR T trial for relapsed myeloma targeting GPRC5D
This Phase 1 trial tests a CAR T-cell treatment made to find a specific marker called GPRC5D on myeloma (or plasma cell leukemia) cells. It may help people whose disease has returned or hasn’t responded to several prior treatments.
ShanghaiAges 18–75 - NCT05915442RecruitingPhase 2
Adenosine blocker plus immunotherapy for limited prostate spread
This Phase 2 study tests a medicine that affects “adenosine” signaling along with an immune checkpoint inhibitor (immunotherapy) in men with hormone-sensitive prostate cancer that has spread in only a small, limited way. It aims to stop or slow that limited spread by helping the immune system work better.
New York, New YorkAges 18–99 - NCT06665815Recruiting
Screening close family for type 1 diabetes risk
This study screens close family members of people with type 1 diabetes for early signs of the condition. A simple blood test looks for special markers (autoantibodies) that can show if the immune system is starting to attack the pancreas. Finding these markers early may help doctors prevent or delay the onset of diabetes.
Petah TikvaAges 2–45 - NCT06587685RecruitingPhase 3
PG-011 gel for eczema in teens and adults
This trial tests a new gel called PG-011 for people with mild to moderate eczema (atopic dermatitis). The gel is applied to the skin, and the study will check if it helps improve symptoms safely.
Shenyang, LiaoningAges 12–75 - NCT06900920RecruitingPhase 3
Study of TQB3473 tablets for adults with chronic immune thrombocytopenia
This trial tests an investigational tablet called TQB3473 against placebo for adults with primary immune thrombocytopenia (ITP) that has lasted at least a year and hasn't responded well to standard treatments. The goal is to see if the drug can safely increase platelet counts and reduce bleeding risk.
Hefei, AnhuiAges 18–75 - NCT06939660Recruiting
Brain-spinal cord stimulation for walking after spinal cord injury
This trial tests if combining brain-computer interface technology with spinal cord stimulation can help improve walking in people with chronic spinal cord injury. It aims to see if this approach works when standard rehab has stopped helping.
Beijing, Beijing MunicipalityAges 14–65
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,062 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,151 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.